Trial Profile
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess The Pharmacokinetics And Pharmacodynamics Of Pf-04950615 Following Subcutaneous And Intravenous Doses In Adult Subjects With Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Bococizumab (Primary) ; Bococizumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Nov 2012 Pooled analysis presented at the 85th Annual Scientific Sessions of the American Heart Association.
- 29 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 29 Mar 2012 Actual patients number is 49 as reported by ClinicalTrials.gov.